Palatin Technologies PTN
NASDAQ PTN
$12.02 -0.31 (-2.51%)
At close: Sep 10, 2026 · 4:00 PM EDT

Palatin Technologies (PTN) Common Equity (2011 - 2026)

Palatin Technologies' (PTN) quarterly Common Equity came in at $10.6 million in Q1 2026, up 265.83% on a YoY basis from $2.9 million in Q1 2025, and down 7.62% quarter-over-quarter from $11.5 million in Q4 2025.

Analysis

Palatin Technologies (PTN) Common Equity (2011 - 2026) Analysis & Trends

Palatin Technologies (PTN) has reported Common Equity for 16 consecutive years, with $10.6 million the latest figure, recorded in Q1 2026.

  • For the quarter ending Q1 2026, Common Equity rose 265.83% year-over-year to $10.6 million; the trailing twelve-month figure through Mar 2026 stood at $10.6 million (up 265.83% YoY), and the FY2025 full-year result was -$4.8 million, down 4184.46% from the prior year.
  • Common Equity fell to $10.6 million in Q1 2026 per PTN's latest filing, from $11.5 million in the prior quarter.
  • Across five years, Common Equity topped out at $28.1 million in Q1 2022 and bottomed at -$11.4 million in Q4 2023.
  • Historically, Common Equity has averaged $2.9 million across 5 years, with a median of $396399.0 in 2025.
  • The widest YoY moves for Common Equity: up 279.69% in 2025, down 4184.46% in 2025.
  • Over 5 years, Common Equity stood at $11.5 million in 2022, then plunged by 198.73% to -$11.4 million in 2023, then jumped by 43.95% to -$6.4 million in 2024, then soared by 279.69% to $11.5 million in 2025, then fell by 7.62% to $10.6 million in 2026.
  • According to Business Quant data, Common Equity over the past three periods registered $10.6 million, $11.5 million, and $396399.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Common Equity (Qtr)
1 Amgen 206.44 Bn 192.45 Bn 7.24 Bn 11.69 Bn
2 Gilead Sciences 179.97 Bn 176.79 Bn 6.22 Bn 11.83 Bn
3 Vertex Pharmaceuticals 130.57 Bn 122.72 Bn 2.84 Bn 20.25 Bn
4 Regeneron Pharmaceuticals 81.63 Bn 73.63 Bn 3.93 Bn 31.71 Bn
5 Argenx Se 60.34 Bn 55.16 Bn 1.37 Bn 8.42 Bn
6 Moderna 54.37 Bn 49.23 Bn 52.00 Mn 6.76 Bn
7 Alnylam Pharmaceuticals 33.07 Bn 29.76 Bn 992.69 Mn 1.35 Bn
8 Biogen 31.84 Bn 30.55 Bn 1.96 Bn 18.85 Bn
9 Roivant Sciences 29.49 Bn 29.49 Bn 1.16 Mn 4.92 Bn
10 Palatin Technologies 46.98 Mn 46.98 Mn - 10.59 Mn
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 10.59 Mn
Dec 31, 2025 11.47 Mn
Sep 30, 2025 396,399.00
Jun 30, 2025 -4.78 Mn
Mar 31, 2025 -6.39 Mn
Dec 31, 2024 -6.38 Mn
Sep 30, 2024 -7.69 Mn
Jun 30, 2024 -111,497.00
Mar 31, 2024 1.58 Mn
Dec 31, 2023 -11.38 Mn
Sep 30, 2023 -6.32 Mn
Jun 30, 2023 -1.98 Mn
Mar 31, 2023 6.58 Mn
Dec 31, 2022 11.53 Mn
Sep 30, 2022 8.45 Mn
Jun 30, 2022 16.27 Mn
Mar 31, 2022 28.09 Mn
Dec 31, 2021 35.20 Mn
Sep 30, 2021 42.97 Mn
Jun 30, 2021 49.65 Mn